(Press-News.org) Scientists have used an AI model to reassess the results of a completed clinical trial for an Alzheimer’s disease drug. They found the drug slowed cognitive decline by 46% in a group of patients with early stage, slow-progressing mild cognitive impairment – a condition that can progress to Alzheimer’s.
Using AI allowed the team to split trial participants into two groups: either slowly or rapidly progressing towards Alzheimer’s disease. They could then look at the effects of the drug on each group.
More precise selection of trial participants in this way could help select patients most likely to benefit from treatment, with the potential to reduce the cost of developing new medicines by streamlining clinical trials.
The AI model developed by researchers at the University of Cambridge predicts whether, and how quickly, people at early stages of cognitive decline will progress to full-blown Alzheimer’s. It gives predictions for patients that are three times more accurate than standard clinical assessments based on memory tests, MRI scans and blood tests.
Using this patient stratification model, data from a completed clinical trial - which did not demonstrate efficacy in the total population studied - was re-analysed. The researchers found that the drug cleared a protein called beta amyloid in both patient groups as intended - but only the early stage, slow-progressing patients showed changes in symptoms. Beta amyloid is one of the first disease markers to appear in the brain in Alzheimer’s disease.
The new findings have significant implications: using AI to separate patients into different groups, such as slow versus rapidly progressing towards Alzheimer’s disease, allows scientists to better identify those who could benefit from a treatment approach - potentially accelerating the discovery of much-needed new Alzheimer’s drugs.
The results are published today in the journal Nature Communications.
Professor Zoe Kourtzi in the University of Cambridge’s Department of Psychology, senior author of the report, said: “Promising new drugs fail when given to people too late, when they have no chance of benefiting from them. With our AI model we can finally identify patients precisely, and match the right patients to the right drugs. This makes trials more precise, so they can progress faster and cost less, turbocharging the search for a desperately-need precision medicine approach for dementia treatment.”
She added: “Our AI model gives us a score to show how quickly each patient will progress towards Alzheimer’s disease. This allowed us to precisely split the patients on the clinical trial into two groups – slow, and fast progressing, so we could look at the effects of the drug on each group.”
Health Innovation East England, the innovation arm of the NHS in the East of England, is now supporting Kourtzi to translate this AI-enabled approach into clinical care for the benefit of future patients.
Joanna Dempsey, Principal Advisor at Health Innovation East England, said: “This AI-enabled approach could have a significant impact on easing NHS pressure and costs in dementia care by enabling more personalised drug development - identifying which patients are most likely to benefit from treatment, resulting in faster access to effective medicines and targeted support for people living with dementia.”
Drugs like this are not intended as cures for Alzheimer’s disease. The aim is to reduce cognitive decline so that patients don’t get worse.
Dementia is the UK’s leading cause of death, and a major cause of mortality globally. It costs $1.3 tr per year, and the number of cases are expected to treble by 2050. There is no cure, and patients and families face high uncertainty.
Despite decades of research and development, clinical trials of treatments for dementia have been largely unsuccessful. The failure rate for new treatments is unreasonably high at over 95%, despite $43 bn having been spent on research and development. Progress has been hampered by the wide variation in symptoms, disease progression and responses to treatment among patients.
Although new dementia drugs have recently been approved for use in the US, their risk of side effects and insufficient cost effectiveness have prevented healthcare adoption in the NHS.
Understanding and accounting for the natural differences among individuals with a disease is crucial, so that treatments can be tailored to be most effective for each patient. Alzheimer’s disease is complex, and although some drugs are available to treat it they don’t work for everybody.
“AI can guide us to the patients who will benefit from dementia medicines, by treating them at the stage when the drugs will make a difference, so we can finally start fighting back against these cruel diseases. Making clinical trials faster, cheaper and better, guided by AI has strong potential to accelerate discovery of new precise treatments for individual patients, reducing side effects and costs for healthcare services,” said Kourtzi.
She added: “Like many people, I have watched hopelessly as dementia stole a loved one from me. We’ve got to accelerate the development of dementia medicines. Over £40 billion has already been spent over thirty years of research and development - we can’t wait another thirty years.”
END
AI can accelerate search for more effective Alzheimer’s medicines by streamlining clinical trials
2025-07-17
ELSE PRESS RELEASES FROM THIS DATE:
Neanderthals at two nearby caves butchered the same prey in different ways, suggesting local food traditions
2025-07-17
A new study from the Hebrew University of Jerusalem reveals that Neanderthals living in two nearby caves in northern Israel—butchered their food in noticeably different ways. Despite using the same tools and hunting the same prey, groups in Amud and Kebara caves left behind distinct patterns of cut-marks on animal bones, suggesting that food preparation techniques may have been culturally specific and passed down through generations. These differences cannot be explained by tool type, skill, or available resources, and may reflect practices such as drying or aging meat before butchering. The findings provide rare insight into the ...
Specialty of the house: Neanderthals at two nearby caves butchered the same prey in different ways, suggesting local food traditions
2025-07-17
Did Neanderthals have family recipes? A new study suggests that two groups of Neanderthals living in the caves of Amud and Kebara in northern Israel butchered their food in strikingly different ways, despite living close by and using similar tools and resources. Scientists think they might have been passing down different food preparation practices.
“The subtle differences in cut-mark patterns between Amud and Kebara may reflect local traditions of animal carcass processing,” said Anaëlle Jallon, ...
‘Ultimate dinner party guests’: Dispersed communities attending feast in ancient Iran gifted boars sourced from distant lands
2025-07-17
Magnets and shot glasses serve as fun holiday souvenirs, but certain foods synonymous with a country’s identity can make for extra meaningful gifts for friends and loved ones; think French cheese, Dutch Stroopwafels and Canadian maple syrup.
According to new research, communities that lived in western Iran about 11,000 years ago during the Early Neolithic period took a similar approach when it came to gift-giving.
They invested significant effort to bring wild boars hunted in dispersed parts of ...
Temozolomide and radiation treatment lead to dramatic tumor shrinkage and improvement of hearing in an adult brainstem glioma patient with a rare IDH2 mutation
2025-07-17
Niigata, Japan – A group led by the Department of Neurosurgery at the Brain Research Institute, Niigata University, has successfully treated a patient with a brainstem glioma harboring a rare IDH2 mutation. The patient initially presented with a gradual loss of hearing in the left ear, and MRI showed a lesion at the left side of the brainstem, near the root exit zone of the left acoustic nerve. Initially, a brainstem glioma with H3K27M mutation was suspected. However, the gradual clinical course and unusual location of the brainstem glioma were considered atypical. The patient underwent magnetic resonance spectroscopy in which 2-hydroglutarate, a marker for IDH ...
Unveiling the mystery of electron dynamics in the 'quantum tunneling barrier' for the first time
2025-07-17
Recently, Professor Dong Eon Kim from POSTECH's Department of Physics and Max Planck Korea-POSTECH Initiative and his research team have succeeded in unraveling for the first time the mystery of the 'electron tunneling' process, a core concept in quantum mechanics, and confirmed it through experiments. This study was published in the international journal Physical Review Letters and is attracting attention as a key to unlocking the long-standing mystery of 'electron tunneling,' which has remained unsolved for over 100 years.
While the idea of teleporting ...
Do dogs judge you?
2025-07-17
Kyoto, Japan -- Many people tend to trust dogs' instincts regarding humans. If dogs gravitate towards you, dog lovers will likely see you as safe and trustworthy, but if dogs are apprehensive around you, some may begin to question your character. Yet how and even if dogs socially evaluate people remains a mystery.
Studies have demonstrated that cognitively complex and social animal species -- such as chimpanzees -- can form reputations of humans either through direct interaction or by observing third-party interactions. The historically ...
Human-AI ‘collaboration’ makes it simpler to solve quantum physics problems
2025-07-17
At the forefront of discovery, where cutting-edge scientific questions are tackled, we often don’t have much data. Conversely, successful machine learning (ML) tends to rely on large, high quality data sets for training. So how can researchers harness AI effectively to support their investigations? Published in Physical Review Research, scientists describe an approach for working with ML to tackle complex questions in condensed matter physics. Their method tackles hard problems which were previously unsolvable by physicist simulations or by ML algorithms alone.
The researchers ...
Be Well Texas at UT Health San Antonio to lead major statewide expansion of opioid use disorder and recovery services
2025-07-16
SAN ANTONIO, July 16, 2025 – The Texas Health and Human Services Commission has selected Be Well Texas, an initiative of the Be Well Institute on Substance Use and Related Disorders at The University of Texas Health Science Center at San Antonio (UT Health San Antonio), to lead a major expansion of opioid use disorder and recovery support services across Texas.
Be Well Texas has been awarded funding to administer two key components of the state’s opioid response under a Needs Capacity Assessment initiative: medications for opioid use disorder treatment services and recovery support services.
This initiative is part of the broader Texas Targeted Opioid Response ...
Freshwater fish, too, attracted to artificial root structures
2025-07-16
LAWRENCE – As an avid fly fisherman, Keith Van de Riet spends a lot of time trying to think like a fish does.
He does likewise in his day job as professor at the University of Kansas School of Architecture & Design, having now conducted nearly a dozen experiments seeking to ascertain how fish react to waterfront edges using a variety of underwater seawall panels made to resemble plant roots.
Van de Riet is a co-author of a new paper titled “Multi-Species
Fish Habitat Preferences for Various Modified Concrete Armouring ...
In hard-to-treat form of tuberculosis, shorter, gentler therapy shows unequal benefit
2025-07-16
At a glance:
First-ever clinical trial exclusively conducted among people with hard-to-treat form of tuberculosis known as pre-extensively drug-resistant TB shows many patients benefit from shorter, simpler regimens.
Not all patients benefited from the shorter, gentler course of treatment, prompting researchers to urge caution and carefully evaluate disease severity prior to selecting treatment.
In those with more severe tuberculosis, the new treatment did not always resolve the disease, a finding that highlights the importance of tailored treatment strategies.
Some ...